More than a year after consulting with stakeholders on various options for a naming policy for biologic drugs, Health Canada has decided that such products should be identified by their unique brand name and non-proprietary name, without the addition of a product-specific suffix.
This means that both the brand name and non-proprietary name will be used for identifying biologics, including biosimilars, throughout the...








